Treatment of acute myeloid leukemia in the next decade – Towards real-time functional testing and personalized medicine

Information arising from next generation sequencing of leukemia genome has shed important light on the heterogeneous and combinatorial driver events in acute myeloid leukemia (AML). It has also provided insight as to its intricate signaling pathways operative in the disease pathogenesis. These have also become biomarkers and targets for therapeutic intervention. Emerging evidence from in vitro drug screening has demonstrated its potential value in predicting clinical drug responses in specific AML subtypes.
Source: Blood Reviews - Category: Hematology Authors: Tags: Review Source Type: research